The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...

The U.S. Environmental Protection Agency has drafted a plan to eliminate all limits on greenhouse gases from coal and ...

Microdosing isn’t just popular for psychedelics. Some consumers are taking smaller than standard doses of GLP-1s—the popular ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

By Sriparna Roy (Reuters) -After years of easily available, cheap copies of Eli Lilly's and Novo Nordisk's highly effective ...

By Sriparna Roy (Reuters) -After years of easily available, cheap copies of Eli Lilly's and Novo Nordisk's highly effective ...

Novo Nordisk has launched a direct-to-consumer (DTC) option for uninsured or under-insured people wanting to access its GLP-1 agonist weight-loss drug Wegovy ... rival Eli Lilly adopted a similar ...

Shares in Eli Lilly ... drugs for obesity, Pfizer, abandoned development of its danuglipron candidate after seeing a safety signal in clinical trials. Rival companies trying to develop oral weight ...

Ozempic is an injectable semaglutide medication approved by the Food and Drug ... for weight loss. “Ozempic and the GLP-1 medications have changed the conversation around obesity—now we ...